The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma

• DOI: 10.1039/d0bm00870b
• Publication Date: 2020-11-04T12:15:33Z
• Authors: Kesang Li; Yingyi Ye; Liqin Liu; Qian Sha; Xiaolu Wang; Ting Jiao; Li Zhang; Jinyan Wang
• Keywords: 0301 basic medicine; Mice; 03 medical and health sciences; Tumor Microenvironment; Animals; Membrane Proteins; Nanoparticles; Lipids; Melanoma; 3. Good health

The response rate to PD-1/PD-L1 immune checkpoint inhibition (ICI) therapy in melanoma remains low due to the immunosuppressive tumor microenvironment.